Lymphocytapheresis in the treatment of multiple sclerosis

H. F. McFarland, J. W. Rose

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The use of lymphocytapheresis as immunosuppressive therapy in the treatment of multiple sclerosis (MS) has been the focus of recent interest. Substantial numbers of patients have been treated in uncontrolled trials that have produced conflicting results as to effectiveness. Patients with a rapidly evolving chronic progressive course of disease do not seem to benefit from this treatment. Possibly, stabilization may occur in patients with a slower progressive course. However, definitive conclusions are not possible from current data. At this time lymphocytapheresis in the treatment of MS should be considered an experimental therapy, not used as a routine treatment. Lymphocytapheresis should be evaluated in a well-designed controlled clinical trial.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalPlasma Therapy and Transfusion Technology
Issue number4
StatePublished - 1982
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Hematology


Dive into the research topics of 'Lymphocytapheresis in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this